Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Broggini

Showing results (151-160 of 154) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 154 results.
Oncogene|September 25, 2007
Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancerW N Cooper, R E Dickinson, A Dallol, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2015
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trialE Rulli, M Marabese, V Torri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 21, 2014
Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumorsD Serpico, A Trama, E R Haspinger, et al.
ESMO Open|January 10, 2021
Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapyM Ganzinelli, H Linardou, M F Alvisi, et al.
Pageof 16

Showing results (151-160 of 154) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 154 results.
Oncogene|September 25, 2007
Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancerW N Cooper, R E Dickinson, A Dallol, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2015
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trialE Rulli, M Marabese, V Torri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 21, 2014
Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumorsD Serpico, A Trama, E R Haspinger, et al.
ESMO Open|January 10, 2021
Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapyM Ganzinelli, H Linardou, M F Alvisi, et al.
Pageof 16